COMPASS Pathways
16
1
5
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
6.3%
1 terminated/withdrawn out of 16 trials
88.9%
+2.4% vs industry average
19%
3 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Role: lead
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Role: lead
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Role: collaborator
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Role: lead
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Role: lead
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Role: lead
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Role: collaborator
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
Role: lead
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Role: collaborator
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
Role: collaborator
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Role: lead
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Role: lead
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
Role: collaborator
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Role: collaborator
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
Role: lead
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
Role: collaborator
All 16 trials loaded